Israeli aesthetic medical company Hallura, who is developing the next generation of Hyaluronic Acid (HA) Dermal Fillers, has announced the appointment of Paul Navarre as an independent director of the company's Board of Directors.
"We are excited to welcome Mr. Paul Navarre as he brings a wealth of knowledge and experience to Hallura's board," said Dr. Shimon Eckhouse, co-founder and Chairman of Hallura. "His exceptional track record made Paul a respected and well-known executive in the industry. Paul shares our vision on how Hallura's technology is disruptive and can transform the industry. Paul's unique insights will help guide the vision and strategic opportunities of Hallura."
Navarre brings more than 25 years' experience in the pharmaceuticals and consumer goods industries to the Board of Hallura. He recently retired from Ferring Holding Inc., where he was the CEO for nearly three years and managed activities, including commercial operations as well as clinical development and manufacturing. Before that, Navarre served as President of International at Allergan, where he managed a $3 billion specialty care business. Navarre also previously spent 15 years at Procter & Gamble, where he worked in both the consumer goods and pharmaceuticals divisions.
"I am very excited to join the Board of Directors. Hallura is at the forefront of the technology that will allow to access the next generation of aesthetic treatments. The great progresses Hallura did in the last two years make it an exciting time to join the company, and I look forward to bringing my experience to the Board," said Navarre.